CELCCelcuity Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key: 13264
Ticker: CELC
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2017-09-20
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: CELC

Detail

Enriched 2026-08-14 20:47

Market cap: $4,490,399,799.04
Shares outstanding (class): 48,766,288
Shares outstanding (weighted): 48,766,288
SIC: 8071 SERVICES-MEDICAL LABORATORIES
Employees: 155
Location: MINNEAPOLIS, MN
Homepage: https://www.celcuity.com
Description: Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Market cap and share counts drift.

Funds holding this security

126 funds · 129 positions · $691.14M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$152.42M	0.01%	1,335,339 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$97.77M	0.14%	856,555 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$83.54M	1.12%	731,925 NS	FIGI
T. Rowe Price Health Sciences Fund, Inc. T. ROWE PRICE HEALTH SCIENCES FUND, INC.	—	$60.61M	0.56%	531,000 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$45.95M	0.06%	402,568 NS	FIGI
Artisan International Small-Mid Fund Artisan Partners Funds Inc.	—	$32.33M	1.21%	283,245 NS	FIGI
iShares Russell 2000 Growth ETF iShares Trust	IWO	$31.07M	0.26%	272,241 NS	FIGI
T. Rowe Price New Horizons Fund, Inc. T. ROWE PRICE NEW HORIZONS FUND, INC.	—	$28.09M	0.22%	246,068 NS	FIGI
Eventide Healthcare & Life Sciences Fund MUTUAL FUND SERIES TRUST	—	$27.72M	1.75%	242,873 NS	FIGI
T. Rowe Price Integrated U.S. Small-Cap Growth … T. ROWE PRICE INTEGRATED EQUITY FUNDS, INC.	—	$14.36M	0.17%	125,840 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$10.10M	0.83%	88,463 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$6.51M	0.13%	57,019 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$5.16M	0.01%	45,228 NS	FIGI
Bridge Builder Small/Mid Cap Growth Fund Bridge Builder Trust	—	$4.66M	0.05%	40,807 NS	FIGI
Driehaus Micro Cap Growth Fund Driehaus Mutual Funds	—	$4.40M	0.96%	38,579 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERCELC
FIGI_COMPOSITEBBG00HKBW045
FIGI_SHARE_CLASSBBG00HKBW054
CIK0001603454
ISINUS15102K1007
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Health Care Providers
Source: LLMunreviewed
Self-reported confidence: 0.9
Model: deepseek
Rationale: Celcuity is a medical laboratory services company, classified under healthcare providers.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.